S. Blesson

发表

Low antileishmanial drug exposure in HIV-positive visceral leishmaniasis patients on antiretrovirals: an Ethiopian cohort study

J. Beijnen, A. Hailu, T. Dorlo, 2020, The Journal of antimicrobial chemotherapy.

Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial

A. Tarral, S. Blesson, C. Lumbala, 2018, The Lancet.

In-Hospital Safety in Field Conditions of Nifurtimox Eflornithine Combination Therapy (NECT) for T. b. gambiense Sleeping Sickness

Salah Ghabri, Johannes Blum, S. Blesson, 2012, PLoS neglected tropical diseases.

Oral fexinidazole for stage 1 or early stage 2 African Trypanosoma brucei gambiense trypanosomiasis: a prospective, multicentre, open-label, cohort study

A. Tarral, S. Blesson, C. Lumbala, 2021, The Lancet. Global health.

Effectiveness of Nifurtimox Eflornithine Combination Therapy (NECT) in T. b. gambiense second stage sleeping sickness patients in the Democratic Republic of Congo: Report from a field study

C. Burri, S. Blesson, V. Kande, 2021, PLoS neglected tropical diseases.

A DBS method for quantitation of the new oral trypanocidal drug fexinidazole and its active metabolites.

S. Blesson, Olaf Valverde Mordt, G. Sanderink, 2016, Bioanalysis.

A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia

J. Alvar, N. Alexander, A. Hailu, 2019, PLoS neglected tropical diseases.

Low risk of death, but substantial program attrition, in pediatric HIV treatment cohorts in Sub-Saharan Africa

Leroy, M. Newell, P. Miotti, 2008 .

Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives

B. Arana, G. Bilbe, S. Monnerat, 2018, Clinical Microbiology Reviews.

Safety and efficacy of oral fexinidazole in children with gambiense human African trypanosomiasis: a multicentre, single-arm, open-label, phase 2–3 trial

A. Tarral, S. Blesson, C. Lumbala, 2022, The Lancet. Global health.

Analysis of the mechanisms of human cytotoxic T lymphocyte response inhibition by NO.

F. Mami-Chouaib, S. Chouaib, J. Thiery, 2002, International immunology.

Determination of an Optimal Dosing Regimen for Fexinidazole, a Novel Oral Drug for the Treatment of Human African Trypanosomiasis: First-in-Human Studies

M. A. Bray, Els Torreele, Michael A. Bray, 2014, Clinical Pharmacokinetics.

Validation and Clinical Evaluation of a Novel Method To Measure Miltefosine in Leishmaniasis Patients Using Dried Blood Spot Sample Collection

J. Schellens, H. Rosing, J. Beijnen, 2016, Antimicrobial Agents and Chemotherapy.

Long term outcomes and prognostics of visceral leishmaniasis in HIV infected patients with use of pentamidine as secondary prophylaxis based on CD4 level: a prospective cohort study in Ethiopia

J. van Griensven, J. Alvar, N. Alexander, 2019, PLoS neglected tropical diseases.

Host transcriptomic signature as alternative test-of-cure in visceral leishmaniasis patients co-infected with HIV

P. Kaye, B. Cuypers, J. van Griensven, 2020, EBioMedicine.

Improving the Quality of Host Country Ethical Oversight of International Research: The Use of a Collaborative 'Pre-Review' Mechanism for a Study of Fexinidazole for Human African Trypanosomiasis.

A. Dhai, A. Tarral, M. Mamzer-Bruneel, 2015, Developing world bioethics.

Determination of the Optimal Single Dose Treatment for Acoziborole, a Novel Drug for the Treatment of Human African Trypanosomiasis: First-in-Human Study

A. Tarral, S. Blesson, Sophie Delhomme, 2023, Clinical Pharmacokinetics.

The anti-angiogenic activity of IL-12 is increased in iNOS−/− mice and involves NK cells

P. Opolon, O. Bawa, S. Chouaib, 2010, Journal of Molecular Medicine.

Compliance with infection control practices in sputum microscopy centres: a study from Kerala, India.

H. Shewade, S. Nagaraja, S. Blesson, 2015, Public health action.

Determination of an Optimal Dosing Regimen for Fexinidazole, a Novel Oral Drug for the Treatment of Human African Trypanosomiasis: First-in-Human Studies Antoine TarralSeverine BlessonOlaf Valverde Mordt • Els TorreeleDaniela SassellaMichael A. BrayLionel Hovsepian • Eric EveneVirginie GualanoMathie

M. A. Bray, A. Tarral, S. Blesson, 2014 .

Host transcriptomic signature as alternative test-of-cure in visceral leishmaniasis patients co-infected with HIV

P. Kaye, J. van Griensven, S. Blesson, 2020, EBioMedicine.